Merck Emerging Markets President Kevin Ali On The Branded Generics Business: An Interview With PharmAsia News (Part 2 of 2)
This article was originally published in PharmAsia News
Executive Summary
When Merck & Co. Inc. Emerging Markets President Kevin Ali speaks of innovation, it is emblematic of Merck's deep-rooted focus on new drug discovery, but the veteran executive now sees opportunities in the differentiated, branded generics segment. On a recent visit to India, Ali spoke to PharmAsia News' India Bureau about incrementally innovative drugs, access to affordable medicines and also Merck's plans in the BRIC-MT nations.
You may also be interested in...
Merck Ties Up With Zhifei To Distribute Gardasil In China, But What Happened To Sinopharm?
Merck has expanded its collaboration with Zhifei, its vaccine partner in China, by signing a three-year RMB 4.5 billion distribution deal for HPV vaccine Gardasil. But left unanswered is whether Merck will walk away from a partnership with Sinopharm it had previously emphasized.
Merck Ties Up With Zhifei To Distribute Gardasil In China, But What Happened To Sinopharm?
Merck has expanded its collaboration with Zhifei, its vaccine partner in China, by signing a three-year RMB 4.5 billion distribution deal for HPV vaccine Gardasil. But left unanswered is whether Merck will walk away from an intended partnership with Sinopharm it had previously emphasized.
Emerging Views On Emerging Markets: JP Morgan Healthcare Conference (Part 1 of 2)
Emerging markets continued to play a large role in company presentations during the industry’s largest investor conference. PharmAsia News takes a closer look.